deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01787474

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Conditions Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia
Interventions Cytarabine Filgrastim Filgrastim-sndz Fludarabine Phosphate Laboratory Biomarker Analysis Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Updated 17 times since 2017 Last updated: Jun 18, 2021 Started: May 19, 2014 Primary completion: Jun 17, 2021 Completion: Jun 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01787474, this PHASE1 trial focuses on Recurrent Adult Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 17 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Dec 2020 · 13 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

▶ Show 12 earlier versions

  1. Nov 2019 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  2. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations